Compare FTCI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | EQ |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 129.0M |
| IPO Year | 2021 | 2018 |
| Metric | FTCI | EQ |
|---|---|---|
| Price | $5.04 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $10.80 | $8.00 |
| AVG Volume (30 Days) | 90.5K | ★ 928.7K |
| Earning Date | 05-01-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | $41,095,000.00 |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $3.21 | $0.29 |
| 52 Week High | $12.75 | $3.45 |
| Indicator | FTCI | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 61.60 |
| Support Level | $4.20 | $1.54 |
| Resistance Level | $5.31 | $3.45 |
| Average True Range (ATR) | 0.48 | 0.35 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 45.98 | 65.57 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.